in

Covid: 30 blood clot cases found in AstraZeneca recipients in the UK

Covid: 30 blood clot cases found in AstraZeneca recipients in the UK

Prime Minister Boris Johnson receives the Oxford-AstraZeneca Covid vaccine last month

Reuters

The UK’s medicines watchdog says it has identified 30 cases of rare blood clots in people who have had the Oxford-AstraZeneca coronavirus vaccine.

The Medicines and Healthcare products Regulatory Agency (MHRA) insists the benefits of the jab outweigh any risks.

The UK cases reported to the regulator were out of more than 18 million doses given up to and including 24 March.

Concerns over the clots have led countries such as Germany, France and Canada to restrict the jab’s use.

The pharmaceutical company AstraZeneca has said international regulators had found the benefits of its jab outweighed risks significantly.

Like the MHRA, the European Medicines Agency (EMA) and the World Health Organization (WHO) have also said the benefits of taking the vaccine outweigh any risks.

  • AstraZeneca: Is there a blood clot risk?
  • Germany limits use of AstraZeneca Covid jab
  • When will I get my Covid jab?

The MHRA said it had received 22 reports of cerebral venous sinus thromboses (CVST) – where a blood clot forms in the brain – and eight reports of “other thrombosis events with low platelets” following use of the Oxford-AstraZeneca jab, out of a total of 18.1 million doses given up to and including 24 March.

The watchdog said the benefits of the Oxford-AstraZeneca vaccine in preventing Covid-19 infection and its complications continued to outweigh any risks, and urged the public to accept the jab when offered it.

In response to the MHRA’s data, Prof Adam Finn, a member of the Joint Committee on Vaccination and Immunisation (JCVI), insisted taking the vaccine was “by far the safest choice” to minimise the risk of serious illness or death from Covid-19.

He said: “The extreme rarity of these events in the context of the many millions of vaccine doses that have been administered means that the risk-benefit decision facing people who are invited to receive Covid-19 vaccines is very straightforward: receiving the vaccine is by far the safest choice in terms of minimising individual risk of serious illness or death.”

Meanwhile, the MHRA said there had been no reports of blood clots following use of the Pfizer-BioNTech vaccine.

As of 21 March, an estimated 10.8 million first doses of the Pfizer-BioNTech jab had been administered in the UK, the regulator said. It added that around 2.2 million second doses, mostly the Pfizer-BioNTech vaccine, had been administered.

More than 31.3 million people in the UK have received a first dose of a coronavirus vaccine, and almost 500,000 have had a second dose, according to Friday’s daily government figures.

Banner image reading 'more about coronavirus'

  • COVID VACCINE: When can you get it?
  • NEW VARIANTS: How worrying are they?
  • FACE MASKS: When do I need to wear one?
  • TESTING: How do I get a virus test?

Banner

Earlier this week, Germany said it was suspending routine use of the Oxford-AstraZeneca jab for people below the age of 60 due to fears over a link with blood clots.

It was one of several European countries which briefly suspended use of the jab earlier this month pending an EMA review into the possible link to blood clots.

When the EMA declared the vaccine “safe and effective”, Germany and others resumed its use while investigations continued.

But on Tuesday Germany decided to suspend routine use for the under-60s at an emergency meeting of health ministers.

It has reported 31 CVSTs and nine deaths out of 2.7 million people vaccinated. Almost all the cases are reportedly in younger and middle-aged women.

France already limits use of AstraZeneca to those aged over 55 and on Monday, Canada recommended immediately suspending use of the jab in people aged below 55 following reports in Europe.

Chart showing the number of countries using each vaccine. Updated 15 March.

The EMA, which has assessed data from around the world, estimates there is around a one in 100,000 risk of a CVST in people under the age of 60 who have been given the Oxford-AstraZeneca vaccine.

The organisation’s head of safety monitoring, Dr Peter Arlett, said that was “more than we would expect to see”.

James Gallagher, the BBC’s Health and Science correspondent, says that it is uncertain what the background rate of these blood clots in the brain truly is.

Estimates vary from around two cases per million people every year to nearly 16 in every million in normal times and coronavirus itself may be causing them too.

CVSTs are inherently more common in younger women and taking the pill increases the risk. So the natural risk levels – whether people are vaccinated or not – could have a role too.

Table comparing the Oxford, Pfizer and Moderna vaccines

Two vaccines – developed by Pfizer-BioNTech and Oxford-AstraZeneca – are currently being used in the UK to protect people against Covid-19.

The first doses of a third vaccine – from Moderna – are due to arrive in the UK later this month. Like the Pfizer-BioNTech and Oxford-AstraZeneca jabs, Moderna’s is given in two doses several weeks apart.

The UK has ordered seven vaccines and expects to receive 407 million doses – more than enough for every adult to receive two.

The aim is to vaccinate everyone aged 18 or over in the UK with one dose by the end of July – but children could receive a vaccine in the long term if they are shown to be safe.

Around the BBC iPlayer banner

  • MEET THE KHANS: Amir and Faryal let us peek into their crazy, fabulous life in Bolton
  • COVID UNDERCOVER: Revealing undercover footage of a Covid testing lab and what is really happening

Around the BBC iPlayer footer

Published at Fri, 02 Apr 2021 15:09:38 +0000

What do you think?

Written by Riel Roussopoulos

Comments

Leave a Reply

Your email address will not be published.

Loading…

0

B.C. officials announce 832 new COVID-19 cases, 53 in Island Health – CHEK

Louisiana Survivors Affected by Severe Winter Storms Reminded to Apply for Federal Disaster Assistance